Investors
Information Disclosure
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 20252025.09.01
-
VOLUNTARY ANNOUNCEMENT - ZONGERTINIB TABLETS APPROVED FOR MARKETING2025.08.29
-
VOLUNTARY ANNOUNCEMENT - DATA FROM FOUR STUDIES OF "TQC3721 (PDE3/4 INHIBITOR)", "TQC2731 (TSLP MONOCLONAL ANTIBODY)" AND "TQC3403 (UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE POWDER FOR INHALATION)" PRESENTED AT ERS 20252025.08.25
-
VOLUNTARY ANNOUNCEMENT - HER2-SELECTIVE TKI "ZONGERTINIB" ONCE AGAIN GRANTED BREAKTHROUGH THERAPEUTIC DESIGNATION BY CDE2025.08.20
-
VOLUNTARY ANNOUNCEMENT - LM-302 "CLDN18.2 ADC" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS2025.08.19
-
Cash Dividend Announcement for Equity Issuer2025.08.19
-
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 20252025.08.18
-
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF TQB3142 “BcL-xL PROTAC”ACCEPTED BY NMPA2025.08.12